Hosted on MSN55m
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
AFP40m
Novotech Releases Report on Current State of Triple-Negative Breast Cancer Clinical Trials
Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for ...